Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22441262 | 1.00 | CTSK (0.52) | CTSKEPHX2TAS1R3TAS1R1KDM4E | |
| SCHEMBL29368864 | 0.88 | TAS1R3 (0.61) | CTSKEPHX2TAS1R3TAS1R1MEN1 | |
| SCHEMBL22441253 | 0.85 | TAS1R3 (0.52) | CTSKTAS1R3TAS1R1MEN1ALDH1A1 | |
| SCHEMBL22441250 | 0.85 | TAS1R3 (0.52) | CTSKTAS1R3TAS1R1MEN1ALDH1A1 | |
| SCHEMBL30760647 | 0.85 | CTSK (0.60) | CTSKEPHX2TAS1R3TAS1R1LPAR3 | |
| SCHEMBL28678349 | 0.85 | CTSK (0.60) | CTSKEPHX2TAS1R3TAS1R1LPAR3 | |
| SCHEMBL22457812 | 0.85 | CTSK (0.60) | CTSKEPHX2TAS1R3TAS1R1LPAR3 | |
| SCHEMBL22441350 | 0.83 | CTSK (0.43) | CTSKEPHX2TAS1R3TAS1R1KDM4E | |
| SCHEMBL22441353 | 0.83 | CTSK (0.43) | CTSKEPHX2TAS1R3TAS1R1KDM4E | |
| SCHEMBL22441334 | 0.83 | TAS1R3 (0.55) | CTSKEPHX2TAS1R3TAS1R1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | VENTHERA, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | CTSK 820/4885EPHX2 1687/4885TAS1R3 3730/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | CTSK 820/4885EPHX2 1687/4885TAS1R3 3730/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | CTSK 820/4885EPHX2 1687/4885TAS1R3 3730/4885 |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, SLC40A1, GPX4 | CTSK 632/4885EPHX2 2435/4885TAS1R3 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.